2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 123

Association Of Rheumatic Diseases With Symptom Severity, Quality Of Life, and Treatment Outcome In Patients With Fibromyalgia
Abstract Number: 2431

Association Of T Follicular Helper / Th17 T Cell and Memory B Cell Populations In Rheumatoid Arthritis With Disease Activity and Therapy With TNF Antagonists
Abstract Number: 1630

Association Of TREM-Like Transcript-1 With Systemic Lupus Erythematosus
Abstract Number: 247

Associations Between Levels Of Urinary C-Telopeptide Fragments Of Type II Collagen and Knee Structure In Asymptomatic Middle-Aged Women
Abstract Number: 2672

Associations Between Popliteal Artery Wall Thickness and Knee Structure In Adults Without Clinical Knee Disease: A Prospective Cohort Study
Abstract Number: 1378

Associations Of Periodontitis (PD) With Established Seropositive Rheumatoid Arthritis are Independent of Smoking and Other Risk Factors
Abstract Number: 1815

Asymmetric Dimethylarginine Levels In The Early Detection Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension
Abstract Number: 220

Asymptomatic Myocardial Ischemic Disease In Takayasu’s Arteritis: Detection By Magnetic Resonance Imaging
Abstract Number: 887

Atherosclerosis and Cardiovascular Disease In Systemic Lupus Eryhematosus Are Related To An Inflammatory/Oxidative Status Linked To The Autoimmune Condition and The Clinical Activity Of The Disease. Effect Of Statins Treatment
Abstract Number: 2898

Atherosclerosis In Systemic Lupus Erythematosus (SLE) and Controls, -An Analysis Of SLE Subgroups
Abstract Number: 479

Attainment Of Remission, Functional, and Quality Of Life Improvements With Golimumab Treatment In Rheumatoid Arthritis Are Associated With Patient Expectations
Abstract Number: 549

Augmented Megakaryopoiesis Supports Accumulation Of Plasma Cells In Lupus-Prone Mice
Abstract Number: 17

Autoantibodies Against Component Of Complement One Contribute To The Complement Activation and Clinical Manifestation Of Antiphospholipid Syndrome (APS) Especially In Refractory Cases
Abstract Number: 2067

Autoantibodies Associated With Inflammatory Myopathy and Other Systemic Autoimmune Rheumatic Diseases In Sera From Breast Cancer Patients
Abstract Number: 26

Autoantibodies Directed Against Cell Surface Components In Autoimmune Disease Patients: Proposal Of a Novel ELISA For The Detection Of Anti-Endothelial Cell Antibodies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].